ITHACA Study

Version/Date: 2.6.2 / 07.07.22



REC Reference: 21/NS/0142

IRAS number: 298986

# Participant Information Sheet – 16 years and over

We would like to invite you to take part in our research study. Before you decide, it is important that you understand why the research is being done and what it would involve for you.

Part 1 tells you the purpose of this study and what will happen to you if you take part.

Part 2 gives you more detailed information about the conduct of the study.

Please take time to read this information carefully and discuss it with others if you wish. If there is anything that is not clear, or if you would like more information, please feel free to ask us.

# Part 1 – To give you first thoughts about the study

#### What is the purpose of the study?

After an organ transplant, patients on lifelong anti-rejection medications (known as immunosuppressive treatment) have a small risk of developing post-transplant lymphoproliferative disease (PTLD). This occurs when a group of white blood cells called 'B cells' grow out of control and transform (change) into cancerous cells. Most cases of PTLD are caused by infection of 'B cells' by a very common virus called Epstein-Barr Virus (EBV) which can also cause glandular fever.

Whilst most people with transplants **DO NOT** develop PTLD, the risk is slightly higher after a heart transplant compared to most other organs (1 in every 10 heart transplant patients under 18 years old will develop PTLD). The reason for this increased risk is still poorly understood. Our previous study showed that very early removal of the thymus (a gland in the neck needed to develop a healthy immune system) during major childhood heart surgery might play an important role in this.

The purpose of this study is to examine the quantity and function of different immune cells circulating in the blood just before transplant and at regular periods after transplant. We will also look at how well the immune system is able to produce antibodies and other specific immune cells to fight an EBV infection. We intend to compare the immune cell patterns of patients undergoing a heart transplant with those

Version/Date: 2.6.2 / 07.07.22

receiving other types of organ transplants. This will help us to better understand how the immune system recovers after transplant and identify immune patterns that either protect patients from developing PTLD or increase their risk of getting the disease.

REC Reference: 21/NS/0142

# Why have I been invited to participate in this study?

We are inviting patients under 18 years old from around the UK, who like you, have been put on the transplant waiting list. We aim to involve 40 participants in this study.

## Do I have to take part?

No, this study is entirely **voluntary**. It is up to you to decide to take part in the study. If you agree to take part, we will first ask you to sign a screening consent form. During the screening consent, we will ask if you agree to have your first study sample taken and stored before your transplant. Once you have been called for your transplant, we will confirm with you that you remain happy to be part of the study and ask you to sign a second consent form. We will not include you in the study or use your blood sample unless you have signed the second consent form.

# Can I take part?

Children with an organ transplant under the age of 18 years are able to take part. In order to be enrolled in the study;

- You must currently live in the UK.
- You should be listed on the national transplant list.

You cannot take part in the study if you:

- Have a pre-existing diagnosis of an inherited or acquired immunodeficiency.
- Have an underlying thymic disorder.
- Have previously received a bone marrow or organ transplant.
- Have had a previous cancer diagnosis.

#### What will happen if I decide to take part?

We will ask you to sign a study consent form to show that you have agreed to take part. We will give you a copy of this to keep as well. We would like to take up to an extra 3 teaspoons of blood during your usual investigations. This will occur during routine appointments with your local transplant team and will not usually require additional hospital visits. The first blood samples will be taken as close to the day of your transplant as possible. We aim to discuss the study with you before taking your first blood samples. However, if your transplant team thinks that this discussion cannot happen at an appropriate time before your transplant, then any blood samples taken for our study will be stored but not used until you have given full consent to be a part of this study. If you decide not to participate in the study, your blood samples will be destroyed as soon as possible. If you do decide to participate in the study, subsequent samples will be taken during your routine follow up clinic visits at 3, 6, 12 and 24 months after your transplant.

At the beginning of the study, we will collect information on your medical history from the transplant team. We will continue to follow up with the transplant team about your

Version/Date: 2.6.2 / 07.07.22

health and clinical progress after each of your routine clinic visits for up to 2 years after your transplant.

REC Reference: 21/NS/0142

# Are there any possible disadvantages or risks from taking part?

Apart from taking a slightly larger blood sample, this research will not affect you. It does **NOT** alter your treatment. Since the blood samples will be taken during your routine transplant tests, there will be no additional pain or discomfort from taking part in this research study.

# What are the possible benefits of taking part?

You will not gain any direct benefit from the study, but the information gathered from our research might help us to better understand how PTLD develops. This is an important step for us to develop future tests that tell us which patients are more likely to develop PTLD. With this knowledge, we could possibly identify ways to reduce the chance of transplant patients getting PTLD and/or create new treatments for this condition.

# Will my taking part in the study be kept confidential?

Yes. All information about you will be kept private. The details are included in Part 2.

# Will my family doctor/General Practitioner (GP) be informed of my participation?

It is optional for your GP to be informed about your participation in the study. If you agree, we will write to your GP to inform them that you have agreed to take part in the study. The letter will explain the aims of the study but will not include any information about your specific blood test results.

#### What if there is a problem?

Any complaint about the way you have been treated during the study or any possible harm you might experience will be addressed. The detailed information on this is given in Part 2.

#### Contact for further information

If you would like any further information about this study, or if you are interested in participating, you could contact:

Name: Dr Ugo Offor

Designation: Consultant Paediatrician

Department: The Sir James Spence Institute,
Royal Victoria Infirmary, Queen Victoria
Road, Newcastle upon Tyne, NE1 4LP.

Tel: +44 (0) 191–282–4068

Name: Dr Ugo Offor

Designation: Paediatric Registrar

Department: The Sir James Spence Institute,
Royal Victoria Infirmary, Queen Victoria
Road, Newcastle upon Tyne, NE1 4LP.

Tel: +44 (0) 191–233–6161

Study email: nuth.ithaca@nhs.net

Version/Date: 2.6.2 / 07.07.22

If the information in Part 1 has interested you and you are considering participation, please continue to read the additional information in Part 2 before making any decision.

REC Reference: 21/NS/0142

# Part 2 – More detailed information you need to know if you still want to take part.

# What will happen to the samples I give?

Your study samples will be analysed in NHS laboratories, Newcastle University research laboratories and other collaborating laboratories in the UK.

If you consent, any of your leftover blood samples can be stored within the Newcastle University biobank and used for future approved research. This is optional; your involvement in this study will not be affected by your decision whether to allow storage and future use of your leftover samples. If you request at any time, your remaining blood samples will be destroyed.

# What will happen if I don't want to carry on with the study?

If at any time you change your mind about being involved with this study, you are free to withdraw without giving a reason. Your decision will not affect the standard of your care in any way. Unless you state otherwise, any blood samples taken while you were involved in the study will continue to be stored and used for research as detailed above. You are free to request that your blood samples are destroyed at any time during or after the study. Any data collected and/or generated up to the time of your withdrawal may still be kept and used for analysis.

#### Will my taking part in the study be kept confidential?

All information that is collected about you during the course of this study will be coded with a study number and kept private. The information will be available to the study team, authorised collaborators, ethical review committee, Newcastle University and the study sponsor (The Newcastle upon Tyne Hospitals NHS Foundation Trust), who can ask to access the study data to ensure that we are complying with research study regulations. They are all bound by the same confidentiality rules.

Every effort will be taken to maintain your privacy. Information about you may be stored electronically on an NHS secure server, and paper documents will be kept in a key-locked filing cabinet or restricted access office at the Sir James Spence Institute, Royal Victoria Infirmary. Study results will be published in a scientific journal but nothing that could identify you will be mentioned in any report or publication.

# How will you use information about me?

As the study sponsor's, The Newcastle upon Tyne Hospitals NHS Foundation Trust is the data controller and is responsible for looking after your information and using in properly. We will need to use information from you and your medical records for this research project. This will include identifiable information such as your name, NHS number, hospital number, and contact details. People will use this information to do

Version/Date: 2.6.2 / 07.07.22

the research or to check your records to make sure that the research is being done properly. We will keep such identifiable information about you for a maximum of 5 years after the study has finished.

REC Reference: 21/NS/0142

People who do not need to know who you are will not be able to see your name or contact details. Your data will have a code number instead. We will keep all information about you safe and secure. We will write our reports in a way that no-one can work out that you took part in the study. De-identified research data will be stored indefinitely at Newcastle University.

# What are my choices about how my information is used?

You can stop being part of the study at any time, without giving a reason, but we will keep any information about you that we have already collected.

We need to manage your records in specific ways for the research to be reliable. This means that we won't be able to let you see or change the data we hold about you.

# Where can I find out more about how my information is used?

You can find out more about how we use your information:

- at <u>www.hra.nhs.uk/information-about-patients/</u>
- · by asking a member of our research team
- by sending an email to richard.oliver2@nhs.net, or
- by ringing us on 0191-213-8946.

#### What will happen to the results of the study?

The results of the study will be published in medical journals which are available via the internet and may also be presented at national/international conferences. Your name will not be used when the research results are published. The study is expected to run for at least 2 years.

# How have patients and the public been involved in this study?

Potential participants were involved in reviewing the Participant Information Sheet. In designing this study, we have taken into account patient opinions on the frequency of participant visits and the tests that we will carry out.

# Who is sponsoring, organising and funding the study?

The study is organised and sponsored by The Newcastle upon Tyne Hospitals NHS Foundation Trust. The study is funded through financial support from Cancer Research UK and the Lymphoma Research Trust. None of the researchers are paid for recruiting you into the study.

REC Reference: 21/NS/0142 ITHACA Study IRAS number: 298986

Version/Date: 2.6.2 / 07.07.22

# Who has reviewed and approved the study?

All research in the NHS is looked at by an independent group of people, called a Research Ethics Committee to protect your safety, rights, wellbeing and dignity. This study has been reviewed and given a favourable opinion by North of Scotland (2) Research Ethics Committee.

# What if something goes wrong?

The study team recognise the important contribution that volunteers make to medical research and make every effort to ensure your safety and well-being. The Newcastle upon Tyne Hospitals NHS Foundation Trust, as the study sponsor, has arrangements in place in the unlikely event that you suffer any harm as a direct consequence of your participation in this study.

In the event of harm being suffered, while the Sponsor will cooperate with any claim, you may wish to seek independent legal advice to ensure that you are properly represented in pursuing any complaint. The study doctor can advise you of further action and refer you to a doctor within the NHS for treatment, if necessary. NHS indemnity operates in respect of the clinical treatment which may be provided if you needed to be admitted to hospital.

# **Complaint statement**

# What if I wish to complain about the way in which the study has been conducted?

If you have a concern about any aspect of this study, you should ask to speak to the researcher investigators who will do their best to address your concerns. Alternatively, you may wish to send us an email at **nuth.ithaca@nhs.net**. If you remain unhappy and wish to complain formally, the normal National Health Service complaints mechanism is available to you. You will not be treated any differently if you decide to make a complaint. You can contact the Patient Advise and Liaison Service (PALS). This service is confidential and can be contacted on Freephone: 0800 032 0202.

Alternatively, if you wish to make a formal complaint you can contact the Patient Relations Department through any of the details below:

Telephone: 0191-223-1382 or 0191-223-1454

Email: patient.relations@nuth.nhs.uk Address: Patient Relations Department

The Newcastle upon Tyne Hospitals NHS Foundation Trust

The Freeman Hospital Newcastle upon Tyne

NE7 7DN

# Further information and contact details

Information Sheet for ages 16 years and over

ITHACA Study IRAS number: 298986

Version/Date: 2.6.2 / 07.07.22

We hope this information sheet has answered all of your questions. If you would like further information about participating in research, please visit the following website: <a href="https://www.crn.nihr.ac.uk/can-help/patients-carers-public/how-to-take-part-in-a-study">www.crn.nihr.ac.uk/can-help/patients-carers-public/how-to-take-part-in-a-study</a>. or you could contact the hospital Clinical Research Facility:

REC Reference: 21/NS/0142

nuth.paedoncresearch@nhs.net

01912821893 (Clinical Lead)

01919177591 (Research Nurse)